Long-Acting Injectable HIV Therapy Outcomes Among Persons With HIV Who Have Adherence Challenges to Oral Antiretroviral Therapy
Elizabeth Hastie, Lucas Hill, Laura Bamford, Afsana Karim, Thomas Martin
Abstract
Long-acting injectable cabotegravir/rilpivirine (LAI-CAB/RPV) may improve outcomes among persons with human immunodeficiency virus (PWH) with adherence difficulties to oral therapy. In this real-world observational study, over 85% of PWH remained on therapy and virally suppressed 48 weeks after initiating LAI-CAB/RPV. Providers should consider LAI therapy among PWH with adherence difficulties.
Topics & Concepts
MedicineRilpivirineAntiretroviral therapyObservational studyHuman immunodeficiency virus (HIV)Medication adherenceIntensive care medicineViral loadInternal medicineFamily medicineHIV/AIDS Research and InterventionsHIV Research and TreatmentHIV/AIDS drug development and treatment